Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent

The epsilon4 allele of apolipoprotein E (apoE) is associated with increased risk for the development of Alzheimer's disease (AD), possibly due to interactions with the beta-amyloid (Abeta) protein. The mechanism by which these two proteins are linked to AD is still unclear. To further assess their potential relationship with the disease, we have determined levels of apoE and Abeta isoforms from three brain regions of neuropathologically confirmed AD and non-AD tissue. In two brain regions affected by AD neuropathology, the hippocampus and frontal cortex, apoE levels were found to be decreased while Abeta(1-40) levels were increased. Levels of apoE were unchanged in AD cerebellum. Furthermore, levels of apoE and Abeta(1-40) were found to be apoE genotype dependent, with lowest levels of apoE and highest levels of Abeta(1-40) occurring in epsilon4 allele carriers. These results suggest that reduction in apoE levels may give rise to increased deposition of amyloid peptides in AD brain.

[1]  D. D'urso,et al.  Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[2]  R. Mahley,et al.  Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. , 1994, Science.

[3]  D. Holtzman,et al.  Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Finch,et al.  Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. , 1995, Brain research. Molecular brain research.

[5]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Breslow,et al.  Human apolipoprotein E isoprotein subclasses are genetically determined. , 1981, American journal of human genetics.

[7]  A. Fagan,et al.  Glial Fibrillary Acidic Protein–Apolipoprotein E (apoE) Transgenic Mice: Astrocyte-Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE3 and apoE4 Lipoproteins , 1998, The Journal of Neuroscience.

[8]  S. Gauthier,et al.  Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and an analysis of several combined studies , 1994, Annals of neurology.

[9]  M. Martini,et al.  Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease , 1999, Neuroscience Letters.

[10]  R. Martins,et al.  Characterization of the Binding of Amyloid‐β Peptide to Cell Culture‐Derived Native Apolipoprotein E2, E3, and E4 Isoforms and to Isoforms from Human Plasma , 1997, Journal of neurochemistry.

[11]  P. Lansbury,et al.  Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Wetzel,et al.  Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. , 1996, Biochemistry.

[14]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[15]  E Brisch,et al.  The Inhibitory Effect of Apolipoprotein E4 on Neurite Outgrowth Is Associated with Microtubule Depolymerization (*) , 1995, The Journal of Biological Chemistry.

[16]  A. Fagan,et al.  Apolipoprotein E-containing High Density Lipoprotein Promotes Neurite Outgrowth and Is a Ligand for the Low Density Lipoprotein Receptor-related Protein* , 1996, The Journal of Biological Chemistry.

[17]  P. Greengard,et al.  Alzheimer Amyloid-β Peptide Forms Denaturant-Resistant Complex with Type ε3 but Not Type ε4 Isoform of Native Apolipoprotein E , 1996, Molecular medicine.

[18]  R. Mahley,et al.  Stable Expression and Secretion of Apolipoproteins E3 and E4 in Mouse Neuroblastoma Cells Produces Differential Effects on Neurite Outgrowth (*) , 1995, The Journal of Biological Chemistry.

[19]  J. Poirier,et al.  Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. , 1999, Brain research. Molecular brain research.

[20]  R. Martins,et al.  Apolipoprotein E promotes the binding and uptake of β-amyloid into Chinese hamster ovary cells in an isoform-specific manner , 1999, Neuroscience.

[21]  G. Utermann,et al.  Genetics of the apolipoprotein E system in man. , 1980, American journal of human genetics.

[22]  S. Young,et al.  Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. , 1991, The Journal of clinical investigation.

[23]  J. Hardy,et al.  Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. , 1998, Human molecular genetics.

[24]  B. Hyman,et al.  Brain Expression of Apolipoproteins E, J, and A‐I in Alzheimer's Disease , 1996, Journal of neurochemistry.

[25]  C. Abraham,et al.  Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. , 1997, Biochemistry.

[26]  G. Getz,et al.  Isoform-specific binding of apolipoprotein E to beta-amyloid. , 1994, The Journal of biological chemistry.

[27]  R. Mahley,et al.  Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. , 1981, The Journal of biological chemistry.

[28]  M. Tremblay,et al.  Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[29]  Z. Khachaturian.  Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.

[30]  J. Poirier,et al.  The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer's disease , 1999, Neuroscience Letters.

[31]  M. Gearing,et al.  Aβ‐peptide length aid apolipoprotein E genotype in Alzheimer's disease , 1996 .

[32]  B. Hyman,et al.  Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.

[33]  R. Mahley,et al.  Human apolipoprotein E. The complete amino acid sequence. , 1982, The Journal of biological chemistry.

[34]  P. Mehta,et al.  Traumatic Brain Injury Increases β‐Amyloid Peptide 1‐42 in Cerebrospinal Fluid , 1998 .

[35]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[36]  R. Demattos,et al.  A Minimally Lipidated Form of Cell-derived Apolipoprotein E Exhibits Isoform-specific Stimulation of Neurite Outgrowth in the Absence of Exogenous Lipids or Lipoproteins* , 1998, The Journal of Biological Chemistry.

[37]  G. Getz,et al.  Association of human, rat, and rabbit apolipoprotein E with β‐amyloid , 1997, Journal of neuroscience research.

[38]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[39]  J. Poirier,et al.  ApoE associated with lipid has a reduced capacity to inhibit β‐amyloid fibril formation , 1998, Neuroreport.

[40]  G. Getz,et al.  Purification of Apolipoprotein E Attenuates Isoform-specific Binding to -Amyloid (*) , 1995, The Journal of Biological Chemistry.

[41]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[42]  J. Poirier,et al.  β‐Amyloid Peptides Increase the Binding and Internalization of Apolipoprotein E to Hippocampal Neurons , 1998, Journal of neurochemistry.

[43]  D. Mann,et al.  Preferential deposition of amyloid β protein (Aβ) in the form Aβ 40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele , 1997, Neuroscience Letters.

[44]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[45]  S. Tsuji,et al.  Aβ1–40 but not Aβ1–42 levels in cortex correlate with apolipoprotein E ϵ4 allele dosage in sporadic Alzheimer's disease , 1997, Brain Research.

[46]  A. Hofman,et al.  Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study , 1998, Neuroscience Letters.

[47]  G. Getz,et al.  Effect of Apolipoprotein E on Neurite Outgrowth and β‐Amyloid‐Induced Toxicity in Developing Rat Primary Hippocampal Cultures , 1997, Journal of neurochemistry.

[48]  M. Tremblay,et al.  Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. , 1997, Journal of lipid research.